Result : It has similar pharmacokinetic properties with low-doses compared to the control group with high-doses.
Bukwang will decide the development direction based on the result.
It is expected to improve the absorption rate and food effect which the conventional treatment(Zytiga) has.
Bukwang will accelerate the development of anti-cancer drugs through joint-management with OCI.
Bukwang Pharmaceutical Co., Ltd. announced the result of SOL-804’s phase 1 clinical trial through Dyna therapeutics, a subsidiary company of Bukwang. The result shows that it has similar pharmacokinetic properties with low-doses compared to the control group with high-doses.
This study is for finding the right dosage of the drug and conducted in Seoul National Univ. hospital with 40 patients. It was compared to a control drug( Zytiga) in the safety, tolerance, and pharmacodynamics characteristics and was conducted in a way of randomized, crossed, and single dose administered.
It is expected to improve the absorption rate and food effect which the conventional treatment(Zytiga) has.
Buwang is going to establish a strategy for the permission with this result of SOL-804’s phase 1 study. This is for the rapid permission and Bukwang will secure the advantage compared to the control drug(Zytiga) through conducting other clinical trials which find out if it would improve food effect.
The subsidiary of Bukwang, Dyna Therapeutics (“Dyna”) registered a composition patent for anti-cancer drug ‘SOL-804’ (Title: Solid oral formulation of lipophilic compound) to the U.S. The patent is also approved in Japan, Eurasia, Europe, Australia, Mexico, and Singapore, etc.
Bukwang said, “They will accelerate the development of anti-cancer medicine which requires great expense through joint management with OCI.”